Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events-Reply

JAMA Oncol. 2021 Oct 1;7(10):1574-1575. doi: 10.1001/jamaoncol.2021.2957.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Immunologic Factors
  • Immunotherapy* / adverse effects
  • Nivolumab*

Substances

  • Immunologic Factors
  • Nivolumab